Protea Biosciences Group Inc. reported earnings results for the fourth quarter and full year ended December 31, 2016. For the quarter, revenue was $869,786, an increase of 47% over fourth quarter of 2015. The loss from operations for the fiscal year ended December 31, 2016 was $5,493,219, compared to a loss from operations of $7,140,143 for 2015. This is a decrease of $1,646,924 or 23% from the prior year. Net cash used in operations was $4,228,360 in fiscal 2016, compared to $5,564,454 in fiscal 2015, a reduction of 24%. For the year, total revenue of $2,446,795, an increase of 31% over fiscal 2015 revenue of $1,861,802. The revenue growth came primarily from its core bioanalytical services business, which grew to $1,778,006 in fiscal 2016, an increase of 91% over fiscal 2015 revenue of $929,076.